XORTX Therapeutics Inc.
Business
XORTX Therapeutics Inc. is a late clinical-stage biotechnology company developing therapies that modulate aberrant purine and uric acid metabolism. Its main products are proprietary formulations and product candidates including XRx-026 (gout/XORLO™), XRx-008 (ADPKD), XRx-101 (AKI associated with respiratory virus infection) and XRx-225 (T2DN). The company organizes around therapeutic development programs and a proprietary formulation platform, supported by patent families, licensing arrangements and third-party contract manufacturing. XORTX pursues regulatory approvals and commercialization in the United States, Europe and other international markets through NDAs/MAAs and collaborations.
Summary from filing dated 2025-05-12
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | — |
| Total assets | $2.68M |
| Total liabilities | $599.1K |
| Stockholders' equity | — |
| Operating cash flow | — |